No Data
No Data
Express News | Sotio Biotech: Biocytogen Will Receive an Upfront Payment and Potential Development Milestone Payments Totaling up to $325.5 Mln
Express News | Sotio Enters Into Multi-Target Antibody Agreement With Biocytogen to Expand ADC Pipeline
BeiGene's Bi-specific Antibody BA3071 and SOTIO Reach Multi-target Antibody Collaboration Agreement.
On July 16th, Gelon Hui announced that Bositum-B (02315.HK) has reached a research cooperation and exclusive selection and license agreement with SOTIO Biotech. According to the agreement, SOTIO is granted the right to acquire licenses for multiple fully human bispecific antibodies produced using Bositum's proprietary RenLite platform, and SOTIO will use these antibodies to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors. The agreement also includes a right for SOTIO to use Bositum's proprietary ADC platform. According to the agreement, Bos
Biosharp-B (02315.HK): RenLite technology platform for light chain mice has been granted a patent in the United States.
On June 21, Glory Hui released an announcement that Baiosaitu-B (02315.HK)'s self-developed RenLite technology platform for whole-body light chain mice has been granted a patent by the United States Patent and Trademark Office. The patent authorization of the key technology of the RenLite platform fully reflects the technical innovation strength and international competitiveness of Baiosaitu, and the company will continue to carry out global patent layout and key technology protection, providing advanced technology platforms and important intellectual property rights for partners.
BIOCYTOGEN-B: 2023 Annual Report
Biosetu-B (02315.HK) is expected to approach the break-even point in 2024 and plans to make further share purchases of no more than HK$10 million
Gelonghui announced on April 11 | Biosetu-B (02315.HK) announced that the company noticed unusual fluctuations in the stock price of the company's shares listed on the Hong Kong Stock Exchange Limited recently. The company hereby explains that there have been no major adverse events in its production and operation activities, and that all business lines have maintained steady growth and are progressing steadily in accordance with the established strategy. The company's board of directors and management team are confident in the company's development prospects and do not expect any significant adverse changes in the company's production and operation activities and financial situation. As disclosed in the overseas regulatory announcement on January 5, 2024, according to the company's careful calculations, the company is expected to reach 20
No Data
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.